The FDA has recently granted approval for use of anti-PD-1 antibodies for treatment of several cancer types including melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, cervical cancer, Merkel cell carcinoma, and head and neck squamous cell carcinoma [1]. The gene discussed is PDCD1; the disease is cancer.